March 6th 2024
Findings from an open-label trial support the FDA approval of inotuzumab ozogamicin as a treatment for pediatric patients with relapsed/refractory acute lymphoblastic leukemia.
February 12th 2024
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
How to Treat Metastatic Malignant Triton Tumor in an Adolescent
A systematic review of reported clinical cases and treatment strategies was performed to better understand the prognostic factors and to develop the best possible treatment option for a 16-year-old patient diagnosed with a malignant triton tumor in the lower extremity with distant metastases in the lungs.
Rare Pediatric Designation Granted by the FDA to Nomacopan for HSCT Thrombotic Microangiopathy
November 10th 2022Findings from a phase 3 trial assessing nomacopan in patients with hematopoietic stem cell transplant–related thrombotic microangiopathy helped to support a rare pediatric designation from the FDA for the agent.
FDA’s ODAC Casts 16 to 0 Vote Against Omburtamab in Pediatric Metastatic Neuroblastoma
November 3rd 2022Members of the FDA’s Oncologic Drugs Advisory Committee indicated there isn’t enough evidence to definitively confirm the overall survival benefit of 131I-omburtamab in pediatric patients with central nervous system or leptomeningeal metastases stemming from neuroblastoma.
FDA Grants Orphan Drug Designation to ET140203 T Cells for Hepatoblastoma
October 19th 2022The FDA has given orphan drug designation to ET140203 ARTEMIS, an investigational therapy for hepatoblastoma, the safety and potential efficacy of which are being evaluated in the phase 1/2 ARYA-1 and ARYA-2 studies.
FDA Approves Rituximab Plus Chemo for Select Pediatric Hematologic Malignancies
December 3rd 2021The FDA has approved rituximab plus chemotherapy for previously untreated pediatric CD20-postive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, and mature B-cell acute leukemia following results from the phase 3 Inter-B-NHL Ritux 2010 study.
In this clinical quandary, investigators determine how to best treat patients with opsoclonus-myoclonus–associated neuroblastoma with bone marrow metastases.
Pediatric Locally Advanced Synovial Sarcoma: What Would Be the Best Treatment Option?
KEY POINTS • Synovial sarcomas are often mistreated with unplanned tumor resection. • Attention from specialists early in the course of SS can minimize the risk of recurrence, metastases, and the necessity for resurgery, all of which are increased with unplanned tumor resection. • Chemotherapy alone does not provide sufficient local control of the tumor. • Resurgery, in conjunction with radiotherapy and chemotherapy, is the best choice of management for this patient.
TBI Plus Etoposide Prior to HSCT Leads to Improved OS, Lower Relapse Risk in High-Risk Pediatric ALL
January 19th 2021Based on recent study results, investigators recommended TBI plus etoposide for patients older than 4 years of age with high-risk ALL undergoing allogeneic hematopoietic stem cell transplantation.
FDA Grants Accelerated Approval to Naxitamab-gqgk Combo for the Treatment of Neuroblastoma
November 30th 2020The FDA granted accelerated approval to naxitamab-gqgk (Danyelza) in combination with GM-CSF for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.
Radiation May Cause Body Composition Abnormalities in Adult Survivors of Pediatric Cancer
October 1st 2020A study found that radiation therapy to treat childhood abdominal and pelvic cancers potentially caused body composition abnormalities and worse cardiometabolic health for adult survivors compared to the general public.
Researchers Receive Grant to Initiate Study of ‘Chemo Brain’ in Pediatric Patients
September 2nd 2020This study is intended to “investigate how chemotherapy disrupts sensory processing, memory, and attention in children; where in the brain the damage is occurring; and whether there is a biomarker that can identify those who are most vulnerable.”
Impact of Radiation Therapy on Survivors of Pediatric Abdominal and Pelvic Tumors
August 28th 2020This study found that abdominal or pelvic radiotherapy was associated with body composition changes that can adversely influence metabolic outcomes and performance status in survivors of abdominal or pelvic tumors.